Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00143117 · ClinicalTrials.gov registry record · Phase 2
Assessment of Efficacy and Safety of UK-390,957 in Men With Premature Ejaculation
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 460
- Enrollment target
NCT00143117: Completed Phase 2 study, sponsored by Pfizer.
NCT00143117 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 460 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (246% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00143117, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 460 participants
- Enrollment target
Study Summary
To determine whether UK-390,957 is an effective and safe treatment for premature ejaculation.
Interventions
- DRUG UK-390,957
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 460 participants |
| Start Date | 2004-08 |
| Est. Completion | 2005-06 |
| Phase | Phase 2 |
What the finished NCT00143117 record still lists
NCT00143117 is an interventional study that assigns participants to a tested intervention. The registered 460 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (246% higher).
The record links to 0 conditions, and to 1 intervention - of which UK-390,957 is the first listed.
NCT00143117 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00143117 about?
NCT00143117 is a clinical study titled "Assessment of Efficacy and Safety of UK-390,957 in Men With Premature Ejaculation". To determine whether UK-390,957 is an effective and safe treatment for premature ejaculation.
What is the current status of trial NCT00143117?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 460 participants. The study started on 2004-08. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00143117?
The interventions under investigation include: UK-390,957 (DRUG).
Who is sponsoring clinical trial NCT00143117?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00143117's enrollment target sits among peer trials
460 83rd of 2000 higher than 1,917 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02977780 · 460 participants · Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
- NCT03427736 · 460 participants
Anesthetics and Analgesics in Children
- NCT03819933 · 460 participants · NA
Optimizing Family Counseling for Anticipated Extremely Preterm Delivery
- NCT04621279 · 460 participants
Cool Prime Comparative Effectiveness Study for Mild HIE
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia